Samsung Epis sets up 1st overseas bio R&D center in Beijing

Samsung Epis Holdings, the holding company of biosimilar drug developer Samsung Bioepis, said Friday it has established a research and development center in China as part of efforts to strengthen its new drug development capabilities. According to the biotech company, it recently set up a wholly owned subsidiary, Samsung Bioepis China, in Beijing’s Changping district as its first overseas R&D foothold. Samsung Epis Holdings, which was launched in November, noted that the establishment of the new

By The Korea Herald